Nothing Special   »   [go: up one dir, main page]

SMT201700052B - 2-(azaindol-2-il)benzimidazoli come inibitori di pad4 - Google Patents

2-(azaindol-2-il)benzimidazoli come inibitori di pad4

Info

Publication number
SMT201700052B
SMT201700052B SM201700052T SM201700052T SMT201700052B SM T201700052 B SMT201700052 B SM T201700052B SM 201700052 T SM201700052 T SM 201700052T SM 201700052 T SM201700052 T SM 201700052T SM T201700052 B SMT201700052 B SM T201700052B
Authority
SM
San Marino
Prior art keywords
benzimidazols
azaindol
pad4 inhibitors
pad4
inhibitors
Prior art date
Application number
SM201700052T
Other languages
English (en)
Inventor
Stephen John Atkinson
Michael David Barker
Matthew Campbell
Hawa Diallo
Clement Douault
Neil Stuart Garton
John Liddle
Robert John Sheppard
Ann Louise Walker
Christopher Wellaway
David Matthew Wilson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of SMT201700052B publication Critical patent/SMT201700052B/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SM201700052T 2012-07-26 2017-01-24 2-(azaindol-2-il)benzimidazoli come inibitori di pad4 SMT201700052B (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2012/064649 WO2014015905A1 (en) 2012-07-26 2012-07-26 2 - (azaindol- 2 -yl) benz imidazoles as pad4 inhibitors

Publications (1)

Publication Number Publication Date
SMT201700052B true SMT201700052B (it) 2017-03-08

Family

ID=49996626

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201700052T SMT201700052B (it) 2012-07-26 2017-01-24 2-(azaindol-2-il)benzimidazoli come inibitori di pad4

Country Status (22)

Country Link
US (4) US9127003B2 (it)
EP (1) EP2877467B1 (it)
JP (1) JP6063567B2 (it)
KR (1) KR101916443B1 (it)
CN (1) CN104470919B (it)
AU (1) AU2012386257B2 (it)
BR (1) BR112015001545B1 (it)
CA (1) CA2879341C (it)
CY (1) CY1118524T1 (it)
DK (1) DK2877467T3 (it)
ES (1) ES2609126T3 (it)
HR (1) HRP20161530T1 (it)
HU (1) HUE033294T2 (it)
IN (1) IN2014KN02935A (it)
LT (1) LT2877467T (it)
PL (1) PL2877467T3 (it)
PT (1) PT2877467T (it)
RS (1) RS55684B1 (it)
RU (1) RU2611010C2 (it)
SI (1) SI2877467T1 (it)
SM (1) SMT201700052B (it)
WO (1) WO2014015905A1 (it)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016264958B2 (en) * 2015-05-21 2020-10-29 Glaxosmithkline Intellectual Property Development Limited Benzoimidazole derivatives as PAD4 inhibitors
AR107030A1 (es) * 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores aza-bencimidazol de pad4
AR107032A1 (es) * 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores bicíclicos de pad4
CA3015482A1 (en) * 2016-02-23 2017-08-31 Padlock Therapeutics, Inc. Heteroaryl inhibitors of pad4
CN107188867A (zh) * 2016-03-14 2017-09-22 中国科学院天津工业生物技术研究所 精氨酸脱亚氨酶4的抑制剂
EP3490989B1 (en) 2016-07-27 2020-09-09 Padlock Therapeutics, Inc. Covalent inhibitors of pad4
MA46193A (fr) * 2016-09-12 2019-07-17 Padlock Therapeutics Inc Inhibiteurs hétéroaryles de pad4
US11208386B2 (en) 2016-12-02 2021-12-28 University Of Massachusetts Inhibitors of protein arginine deiminases (PADs) and methods of preparation and use thereof
CN108689946B (zh) * 2017-04-12 2022-10-18 中国科学院上海药物研究所 2-取代硫基乙酰胺类化合物及其制备方法和应用
BR112020005489A2 (pt) * 2017-09-22 2020-09-24 Jubilant Epipad Llc, composto da fórmula (i), composto de fórmula (ii), composto de fórmula (iii), processo de preparação de compostos de fórmula (i), processo de preparação de compostos de fórmula (ii), processo de preparação de compostos de fórmula (iii), composição farmacêutica, método para inibir uma ou mais famílias pad em uma célula, método para tratar uma afeção mediada por um ou mais pads, utilização do composto, método para o tratamento e/ou prevenção de uma afeção mediada por um ou mais distúrbios da família pad, método para o tratamento de artrite reumatoide e método de tratamento de câncer
BR112020007607A2 (pt) * 2017-10-18 2020-09-29 Jubilant Epipad LLC compostos das fórmulas (i), (ii) e (iii); processos de preparação de compostos das fórmulas (i), (ii) e (iii); composição farmacêutica; compostos; método para a inibição de uma ou mais famílias de pad em uma célula; método de tratamento de uma afecção mediada por uma ou mais pad; composto da fórmula (i), fórmula (ii) e fórmula (iii); uso do composto; método para o tratamento e/ou prevenção de uma afecção; método para o tratamento de artrite reumatoide; e método de tratamento de câncer
AU2018362046B2 (en) 2017-11-06 2023-04-13 Jubilant Prodel LLC Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
ES2979256T3 (es) 2017-11-24 2024-09-25 Jubilant Episcribe Llc Compuestos heterocíclicos como inhibidores de prmt5
EP3760628A4 (en) * 2018-02-26 2021-10-13 Nanjing Transthera Biosciences Co., Ltd. PEPTIDYLARGININE DEIMINASE INHIBITOR AND ITS USES
SG11202008950PA (en) 2018-03-13 2020-10-29 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
JP7447080B2 (ja) 2018-08-08 2024-03-11 ブリストル-マイヤーズ スクイブ カンパニー Pad4阻害剤としての置換チエノピロール
US11524959B1 (en) * 2018-08-08 2022-12-13 Bristol-Myers Squibb Company Indole and azaindole inhibitors of pad enzymes
BR112021002089A2 (pt) * 2018-08-08 2021-05-04 Bristol-Myers Squibb Company benzimidazóis substituídos como inibidores de pad4
ES2956090T3 (es) * 2018-08-08 2023-12-13 Bristol Myers Squibb Co Inhibidores de bencimidazol de enzimas PAD
CN109369513B (zh) * 2018-11-20 2020-08-25 都创(上海)医药科技有限公司 一种fbdd常用分子片段的制备方法
CA3123215C (en) 2018-12-19 2024-04-02 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents
US20230002328A1 (en) * 2019-07-03 2023-01-05 University Of Massachusetts Inhibitors of protein arginine deiminase 1 and methods of preparation and use thereof
CN112574230B (zh) * 2019-09-27 2022-10-28 药捷安康(南京)科技股份有限公司 肽酰精氨酸脱亚胺酶抑制剂及其用途
JP2023512557A (ja) * 2020-02-06 2023-03-27 ブリストル-マイヤーズ スクイブ カンパニー 免疫抑制剤として有用な大環状pad4阻害剤
TW202140477A (zh) * 2020-02-12 2021-11-01 美商必治妥美雅史谷比公司 雜環pad4抑制劑
CN111265526B (zh) * 2020-04-09 2021-03-19 黑龙江中医药大学 一种治疗胃癌的药物及其制备方法
EP4143189A1 (en) 2020-04-30 2023-03-08 Gilead Sciences, Inc. Macrocyclic inhibitors of peptidylarginine deiminases
KR20230093251A (ko) 2020-09-10 2023-06-27 프리시릭스 엔.브이. Fap에 대한 항체 단편
CN116209441A (zh) 2020-09-18 2023-06-02 住友制药株式会社 新型胺衍生物
EP4267562A1 (en) 2020-12-22 2023-11-01 Gilead Sciences, Inc. Inhibitors of peptidylarginine deiminases
TW202329941A (zh) 2021-11-15 2023-08-01 大陸商上海齊魯銳格醫藥研發有限公司 Pad4抑制劑及其用途
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting
WO2023230609A1 (en) * 2022-05-26 2023-11-30 Celgene Corporation Heterocyclic pad4 inhibitors
WO2024109945A1 (en) * 2022-11-24 2024-05-30 Helios Huaming Biopharma Co., Ltd. Selenium containing heterocycle compounds and use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU570439B2 (en) 1983-03-28 1988-03-17 Compression Labs, Inc. A combined intraframe and interframe transform coding system
CN1217654C (zh) 1995-04-14 2005-09-07 史密丝克莱恩比彻姆公司 舒喘宁的计定剂量吸入器
TW533865U (en) 1997-06-10 2003-05-21 Glaxo Group Ltd Dispenser for dispensing medicament and actuation indicating device
JP2002527359A (ja) * 1998-09-18 2002-08-27 ビーエーエスエフ アクチェンゲゼルシャフト キナーゼインヒビターとしての4−アミノピロリピリミジン
US6315112B1 (en) 1998-12-18 2001-11-13 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6352152B1 (en) 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6390291B1 (en) 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6119853A (en) 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
EP1226119B1 (en) 1999-10-19 2005-03-16 MERCK & CO. INC. Tyrosine kinase inhibitors
MXPA02006338A (es) 1999-12-24 2002-12-13 Aventis Pharma Ltd Azaindoles.
GB0115393D0 (en) 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003000690A1 (en) 2001-06-25 2003-01-03 Aventis Pharmaceuticals Inc. Synthesis of heterocyclic compounds employing microwave technology
CN102028994B (zh) 2003-11-03 2013-04-24 葛兰素集团有限公司 流体分配装置
WO2005047289A1 (en) 2003-11-17 2005-05-26 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
FR2862971B1 (fr) * 2003-11-28 2006-03-24 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
US7429611B2 (en) 2004-09-23 2008-09-30 Bristol-Myers Squibb Company Indole inhibitors of 15-lipoxygenase
US20100197657A1 (en) 2007-09-25 2010-08-05 Chang Ronald K 2-aryl or heteroaryl indole derivatives
US20090311217A1 (en) 2008-05-28 2009-12-17 Wyeth 3-substituted-1h-indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
RU2011106786A (ru) * 2008-07-23 2012-08-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибиторы пиразолопиридинкиназы
SG10201401169QA (en) * 2009-04-02 2014-05-29 Merck Serono Sa Dihydroorotate dehydrogenase inhibitors
US20100305093A1 (en) 2009-04-09 2010-12-02 Exelixis, Inc. Inhibitors of mTOR and Methods of Making and Using

Also Published As

Publication number Publication date
PT2877467T (pt) 2017-01-02
AU2012386257A1 (en) 2015-03-12
DK2877467T3 (en) 2017-02-13
HRP20161530T1 (hr) 2017-02-10
US20180161316A1 (en) 2018-06-14
PL2877467T3 (pl) 2017-08-31
EP2877467B1 (en) 2016-11-02
JP6063567B2 (ja) 2017-01-18
US9127003B2 (en) 2015-09-08
US10039755B2 (en) 2018-08-07
EP2877467A1 (en) 2015-06-03
RS55684B1 (sr) 2017-07-31
CN104470919B (zh) 2016-07-06
US9833449B2 (en) 2017-12-05
US20170119750A1 (en) 2017-05-04
CA2879341C (en) 2019-06-11
BR112015001545A2 (pt) 2017-07-04
US20160009716A1 (en) 2016-01-14
US20150175600A1 (en) 2015-06-25
KR20150038438A (ko) 2015-04-08
BR112015001545B1 (pt) 2022-07-05
US9518054B2 (en) 2016-12-13
ES2609126T3 (es) 2017-04-18
CN104470919A (zh) 2015-03-25
AU2012386257B2 (en) 2016-09-08
WO2014015905A1 (en) 2014-01-30
RU2611010C2 (ru) 2017-02-17
JP2015522628A (ja) 2015-08-06
CA2879341A1 (en) 2014-01-30
KR101916443B1 (ko) 2018-11-08
RU2014152456A (ru) 2016-09-20
SI2877467T1 (sl) 2017-02-28
CY1118524T1 (el) 2017-07-12
HUE033294T2 (en) 2017-11-28
LT2877467T (lt) 2017-01-10
IN2014KN02935A (it) 2015-05-08

Similar Documents

Publication Publication Date Title
SMT201700052B (it) 2-(azaindol-2-il)benzimidazoli come inibitori di pad4
CY2022027I1 (el) Παραγωγα βενζιμιδαζολο-προλινης
SMT201600114B (it) Inibitori di beta-secretasi
SMT201700094B (it) Composto di pirazina carbossammide
SMT201700111B (it) Eterociclilammine come inibitori di pi3k
SMT201600311B (it) Inibitori di cdk
SMT201500271B (it) Inibitori di neprilisina
SMT201700065B (it) Derivato piridonico
DK2920168T3 (da) Heterocykliske glutaminase-inhibitorer
DK2841428T3 (da) Dna-pk-inhibitorer
CO6970602A2 (es) Inhibidores de quinasa
DK3178818T3 (da) Pyrazolylquinoxalinkinasehæmmere
DK2710007T3 (da) Kinasehæmmere
DK2895484T3 (da) Glucosylceramidsynthase-inhibitorer
DK2920149T3 (da) 3-aminocycloalkyl-forbindelser som ror-gamma-t-inhibitorer og anvendelser deraf
CO6990736A2 (es) Pirrolidina-2-carboxamidas sustituídas
DK2804858T3 (da) Metalloenzym-inhibitorforbindelser
SMT201600328B (it) Nuovi composti come inibitori di diacilglicerolo aciltransferasi
CU24164B1 (es) Inhibidores sustituidos de acetil-coa carboxilasa
SMT201600357B (it) Inibitori di iap
DK2804611T3 (da) Chitosanafledte forbindelser
DK2934510T3 (da) Lfa-1-inhibitorformuleringer
DE112013005825A5 (de) Reduktionsmittelzuführeinrichtung
BR112014001965A2 (pt) di-cloridrato de denibulin
FR2997080B1 (fr) Inhibiteurs de neprilysine